IDENTIFICATION OF GENETIC ALTERATIONS ASSOCIATED WITH NON-SMALL-CELL LUNG CANCER BY NEXT-GENERATION SEQUENCING
Main Article Content
Abstract
Objective: To identify the rate of certain genetic alterations associated with non-small cell lung cancer. Subjects and Methods: A cross-sectional descriptive study involving 165 patients with non-small cell lung cancer at Hanoi Medical University Hospital, who were tested for genetic alterations using Next-Generation Sequencing. Results: EGFR gene mutation was found in 39% of cases; KRAS gene mutation in 16%; ALK gene fusion in 7%; PIK3CA gene mutation in 2%; BRAF gene mutation in 1%, and ROS-1 gene fusion in 1%. A separate analysis of EGFR mutations revealed: L858R (55.1%); 19 Del (33.3%); 20 Ins (4.3%); A750P (4.3%); G719D (2.9%); G719A (1.5%); E709G (1.5%); E790K (1.5%); S768A (1.5%) and T790M (1.5%). Conclusion: EGFR mutations are the most common mutations in patients with non-small cell lung cancer, with L858R and Exon 19 deletions (19 Del) being the most common types of this gene mutation.
Keywords
Lung cancer, Genetic mutations, Gene fusions, Next-Generation Sequencing (NGS)
Article Details
References
2. Chevallier M, Borgeaud M, Addeo A, et al. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World J Clin Oncol. 2021 Apr 24; 12(4): 217–237. DOI: 10.5306/wjco.v12.i4.217
3. Kumar Ashwini, Kumar Awanish. Non-small-cell lung cancer-associated gene mutations and inhibitors. Advances in Cancer Biology - Metastasis, 6 (2022) 100076. DOI:10.1016/ j.adcanc.2022.100076.
4. Lewandowska MA, Jóźwicki W, Jochymski C, et al. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. Oncol Rep. 2013 Sep; 30(3): 1045-1052. DOI: 10.3892/or.2013.2579
5. Pisapia P, Lozano MD, Vigliar E, et al. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. Cancer Cytopathol . 2017 Nov;125(11):817-830. DOI: 10.1002/cncy.21899.
6. Cainap C, Balacescu O, Cainap SS, et al. Next Generation Sequencing Technology in Lung Cancer Diagnosis. Biology (Basel). 2021 Sep; 10(9): 864. DOI: 10.3390/biology10090864.
7. Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol. 2022 May;17(5):608-622. DOI: 10.1016/j.jtho.2021.12.014.
8. Trần Huy Thịnh, Lê Hoàn, Trần Vân Khánh. Tỷ lệ đột biến EGFR và đột biến dung hợp gen ALK, ROS-1 ở bệnh nhân ung thư phổi không tế bào nhỏ. Tạp chí Y học Việt Nam. 2022; 514(2): 189-193. DOI: https://doi.org/10.51298/vmj. v514i2.2626.
9. Nguyễn Hoàng Bắc, Nguyễn Hữu Huy, Mai Thị Bích Chi và cộng sự. Khảo sát một số đặc điểm cận lâm sàng và tình trạng đột biến gen EGFR, KRAS ở bệnh nhân ung thư phổi không tế bào nhỏ. Tạp chí Y học Việt Nam. 2023; 525(2): 90-93. DOI: https://doi.org/10.51298/vmj. v525i2.5176.
10. Colombino M, Paliogiannis P, Cossu A, et al. (). EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC pulmonary medicine. 2019; 19(1), 1-10. DOI: 10.1186/s12890-019-0964-x.